| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLTA |
| Uniprot No | P09496 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-218aa |
| 氨基酸序列 | MAELDPFGAPAGAPGGPALGNGVAGAGEEDPAAAFLAQQESEIAGIENDEAFAILDGGAPGPQPHGEPPGGPDAVDGVMNGEYYQESNGPTDSYAAISQVDRLQSEPESIRKWREEQMERLEALDANSRKQEAEWKEKAIKELEEWYARQDEQLQKTKANNRAAEEAFVNDIDESSPGTEWERVARLCDFNPKSSKQAKDVSRMRSVLISLKQAPLVH |
| 预测分子量 | 50.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLTA(Clathrin Light Chain A)重组蛋白研究的参考文献示例(内容基于典型研究方向推测，建议通过学术数据库核实具体文献)：
---
1. **标题**: "Recombinant expression and functional characterization of CLTA in clathrin-mediated endocytosis"
**作者**: Smith J, et al.
**摘要**: 研究利用大肠杆菌系统表达重组CLTA蛋白，验证其与clathrin重链(CHC)的相互作用，并证明其在体外囊泡形成中的必要性。通过突变分析揭示了CLTA的特定结构域对膜弯曲功能的调控作用。
2. **标题**: "Structural insights into CLTA dynamics using recombinant protein crystallography"
**作者**: Lee H, et al.
**摘要**: 通过重组CLTA蛋白的结晶和X射线衍射分析，解析了其与适配蛋白AP2的结合界面，揭示了CLTA在clathrin组装过程中的构象变化机制。
3. **标题**: "Development of a CLTA knockout cell line rescued by recombinant CLTA for trafficking studies"
**作者**: Garcia R, et al.
**摘要**: 构建了CLTA基因敲除的HeLa细胞系，并通过转染重组CLTA蛋白恢复内吞功能，证实CLTA在受体介导的胞吞作用中对货物分选的特异性影响。
---
**提示**：建议使用PubMed或Google Scholar，以关键词“CLTA recombinant protein”“clathrin light chain expression”搜索最新文献，重点关注重组表达系统(如原核/真核)、结构功能研究或疾病相关应用方向。
**Background of CLTA Recombinant Protein**
Clathrin Light Chain A (CLTA) is a critical component of clathrin, a protein complex essential for intracellular trafficking, particularly in the formation of clathrin-coated vesicles (CCVs). These vesicles mediate endocytosis and organelle transport, facilitating the uptake of extracellular molecules, membrane protein recycling, and synaptic vesicle formation. CLTA, along with its isoform Clathrin Light Chain B (CLTB), binds to clathrin heavy chains (CHCs) to form the triskelion structure, providing flexibility and regulatory functions. CLTA is implicated in modulating clathrin assembly, interactions with accessory proteins, and adaptor-mediated cargo sorting.
Recombinant CLTA protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to study its biochemical and functional properties. Its production enables researchers to explore CLTA-specific roles in cellular processes, distinct from CLTB, including phosphorylation-dependent signaling and interactions with dynamin or adaptor proteins like AP-2.
CLTA dysregulation is linked to neurological disorders, cancer, and cardiovascular diseases, highlighting its biomedical relevance. Recombinant CLTA serves as a tool for structural studies (e.g., cryo-EM), *in vitro* reconstitution of CCVs, and drug screening targeting clathrin-mediated pathways. It also aids in deciphering post-translational modifications impacting vesicle dynamics. By enabling precise manipulation and analysis, recombinant CLTA advances our understanding of clathrin's role in cellular homeostasis and disease mechanisms.
×
